Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents

Journal of Cardiovascular Magnetic Resonance

Volumn 9, Issue 3, 2007, Pages 565-573

  Neubauer, Anne M ^a   Caruthers, Shelton D ^a,b   Hockett, Franklin D ^a   Cyrus, Tillman ^a   Robertson, J David ^a,c   Allen, J Stacy ^a   Williams, Todd D ^a   Fuhrhop, Ralph W ^a   Lanza, Gregory M ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b PHILIPS HEALTHCARE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Angiography; Carotid Arteries; CMR; Fluorine; Nanoparticles; Perfluorocarbon; Steady state Free Precession

Indexed keywords

CONTRAST MEDIUM; FLUORINE 18; FLUOROCARBON; NANOPARTICLE;

ANGIOCARDIOGRAPHY; ARTICLE; IN VITRO STUDY; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STENOSIS; X RAY;

ANIMALS; CONTRAST MEDIA; CORONARY DISEASE; EMULSIONS; FLUORINE RADIOISOTOPES; FLUOROCARBONS; GADOLINIUM DTPA; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; NANOPARTICLES; OLEIC ACIDS; PHANTOMS, IMAGING; RABBITS;

EID: 33947182975     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1080/10976640600945481     Document Type: Article

References (33)

1. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-75.
2. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1998;78:1157-66.
3. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996;94:928-31.
4. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995:2333-42.
5. MacNeill BD, Lowe HC, Takano M, et al. Intravascular modalities for detection of vulnerable plaque: Current status. Arterioscler Thromb Vasc Biol 2003;23:1333-42.
6. Schoenhagen P, White RD, Nissen SE, et al. Coronary imaging: Angiography shows the stenosis, but IVUS, CT, and MRI show the plaque. Cleve Clin J Med 2003;70:713-19.
7. Kim W Y, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001;345:1863-69.
8. Li D, Deshpande V. Magnetic resonance imaging of coronary arteries. Top Magn Reson Imaging 2001;12:337-47.
9. Choudhury RP, Fayad ZA. Imaging of atherosclerosis. Coronary wall imaging with MRI. J Cardiovasc Risk 2002;9:263-70.
10. Clark LC Jr, Ackerman JL, Thomas SR, et al. Perfluorinated organic liquids and emulsions as biocompatible nmr imaging agents for 19F and dissolved oxygen. Adv Exp Med Biol 1984;180:835-45.
11. Joseph PM, Fishman J E, Mukherji B, et al. In vivo 19F nmr imaging of the cardiovascular system. J Comput Assist Tomogr1985;9:1012-19.
12. Le D, Mason RP, Hunjan S, et al. Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. Magn Reson Imaging 1997;15:971-81.
13. Mason RP, Antich PP. Tumor oxygen tension: Measurement using oxygenttm as a 19F nmr proble at 4.7 t. Artif Cells Blood Substit Immobil Biotechnol 1994;22:1361-67.
14. Ahrens ET, Flores R, Xu H, et al. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005;23:983-87.
15. Caruthers SD, Neubauer AM, Hockett FD, et al. In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol 2006;41:305-12.
16. Morawski AM, Winter PM, Yu X, et al. Quantitative "?magnetic resonance immunohistochemistry"? with ligand-targeted (19)F nanoparticles. Magn Reson Med 2004;52:1255-62.
17. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001;104:1280-85.
18. Lanza GM, Yu X, Winter PM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with an MRI nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 2002;106:2842-47.
19. Landsberger S. Delayed instrumental neutron activation analysis. In Z. B. Alfassi (Ed.), Chemical analysis by nuclear methods New York: John Wiley & Sons;1994:122-140.
20. Winter PM, Caruthers SD, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003;50:411-16.
21. Flaim SF. Pharmacokinetics and side effects of perfluorocarbonbased blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994;22:1043-54.
22. Hunjan S, Zhao D, Canstandtinescu A, et al. Tumor oximetry: Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging the dunning prostate r3327-at1 rat tumor. Int J Radiat Oncol Biol Phys 2001;49:1097-1108.
23. Shukla HP, Mason RP, Bansal N, et al. Regional myocardial oxygen tension: 19F MRI of sequestered perfluorocarbon. Magn Reson Med 1996;35:827-33.
24. Huang MQ, Ye Q, Williams DS, et al. MRI of lungs using partial liquid ventilation with water-in-perfluorocarbon emulsions. Magn Reson Med 1997;48:487-92.
25. Laukemper-Ostendorf S, Scholz A, Burger K, et al. 19F-MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation. Magn Reson Med 2002;47:82-89.
26. Noth U, Grohn P, Jork A, et al. 19F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magn Reson Med 1999;42:1039-47.
27. McFarland E, Koutcher JA, Rosen BR, et al. In vivo 19F nmr imaging. J Comput Assist Tomogr 1985;9:8-15.
28. Busse LJ, Thomas SR, Pratt RG, et al. Deconvolution techniques for removing the effects of chemical shift in 19F nuclear magnetic resonance imaging of perfluorocarbon compounds. Med Phys 1986;13:518-24.
29. Busse LJ, Pratt RG, Thomas SR. Deconvolution of chemical shift spectra in two- or three-dimensional [19F] MR imaging. J Comput Assist Tomogr 1988;12:824-35.
30. Fan X, River JNZamora M, Al-Hallaq HA, et al. Effect of carbogen on tumor oxygenation: Combined fluorine-19 and proton MRI measurements. Int J Radiat Oncol Biol Phys 2002;54: 1202-09.
31. Scheffler K, Lehnhardt S. Principles and applications of balanced SSFP techniques. Eur Radiol 2003;13:2409-18.
32. Graves MJ. Magnetic resonance angiography. Br J Radiol 1997;70:6-28.
33. Moller HE, Chawla MS, Chen XJ, et al. Magnetic resonance angiography with hyperpolarized 129Xe dissolved in a lipid emulsion. Magn Reson Med 1999;41:1058-64.